Prothena Corp PLC (PRTA)

Add to Watchlists
Create an Alert
9.86 -0.14  -1.40% NASDAQ Jul 19, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All PRTA News

News

View All Events

Events

Date Type Description
02/14/2020 16:30 EST Misc Prothena Corp PLC Fourth Quarter Earnings Conference Call in 2019
08/07/2019 Earnings Prothena Corp PLC Second Quarter Earnings Results in 2019
05/21/2019 16:00 IST Misc Prothena Corp PLC Annual General Meeting in 2018
05/07/2019 Earnings Prothena Corp PLC First Quarter Earnings Results in 2019
03/15/2019 Misc Prothena Corp PLC Annual Report in 2018
02/14/2019 16:30 EST Misc Prothena Corp PLC Fourth Quarter Earnings Conference Call in 2018
02/14/2019 Earnings Prothena Corp PLC Fourth Quarter Earnings in 2018 Release
11/06/2018 Earnings Prothena Corp PLC Third Quarter Earnings Results in 2018
08/07/2018 Earnings Prothena Corp PLC Second Quarter Earnings Results in 2018
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 0.914M
Total Expenses (TTM) 117.93M
Net Income (TTM) -127.77M

Balance Sheet View Statement

Total Assets (Quarterly) 459.53M
Total Liabilities (Quarterly) 147.40M
Shareholders Equity (Quarterly) 312.13M

Cash Flow Statement View Statement

Cash from Operations (TTM) -14.13M
Cash from Investing (TTM) -1.671M
Cash from Financing (TTM) -3.135M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.prothena.com
  • Investor Relations URL: http://ir.prothena.com/
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Aug. 07, 2019
  • Last Earnings Release: May. 07, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Prothena Corp PLC is a biotechnology company focuses on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 9.86
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Comparables

Edit
ALKS Alkermes PLC
AMRN Amarin Corp PLC
MMDZF Mainstay Medical International PLC
ENDP Endo International PLC
JAZZ Jazz Pharmaceuticals PLC

Excel Add-In Codes

  • Name: =YCI("PRTA","name")
  • Description: =YCI("PRTA","description")
  • Sector: =YCI("PRTA","sector")
  • Industry: =YCI("PRTA","industry")
  • Est. Current Fiscal Year End: =YCI("PRTA","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.